Protica Bio combines cutting-edge proteomics and machine learning to improve immunotherapy-based clinical decisions and new drug discoveries, with the goal of creating diagnostic capabilities and elevating the response rate for current and future treatments. The company is utilizing a proprietary platform developed by a leading expert in the field of mass spectrometry from the Weizmann Institute. In addition to laboratory research, the company integrates deep proteomics with machine learning to create diagnostic capabilities and elevate the response rate for current and future treatments.